UCB Ventures — Full Portfolio
5 tracked investments · listed companies and verified rows first
Iris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles.
BiotechDeep TechHealthtech
Megan Matthews(Co-founder & President)
Co-investorsVenrockPsyMed Ventures
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)Deepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Dylan Morris(Director)
Board seatAlicia Irurzun-Lafitte· per SEC Form D · $36M raise · filed Nov 2022
Co-investorsBold Capital PartnersCRV (Charles River Ventures)FREEFLOWGlobal BrainOno Venture Investment, Inc.Upfront Ventures+2 more
Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders.
BiotechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Executive Officer)Arnold Kriegstein(Director)
BoardPeter Svennilson(Director)inTim Kutzkey(Director)Ray Kelleher(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalAlexandriaFidelity Investments+7 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.
BiotechDeep TechDigital Health
Kenneth Greenberg(Founder)in
Co-investorsARCH Venture PartnersLeaps by BayerSymBiosisVida VenturesVivo Capital
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsNovartis Venture FundRoche Venture FundSanofi VenturesYsios CapitalAsabys PartnersCriteria Bio Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.